ReviewCurrent opinion in oncology2013
Update on current and potential nanoparticle cancer therapies.
Review in Current opinion in oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Recent advancements in nanoparticles for cancer treatment.Medical oncology (Northwood, London, England) · 2025Review
- Thermoresponsive Chitosan-Grafted-Poly(Pharmaceutics · 2021Review
- Synthesis and Characterization of Chitosan-Based Nanodelivery Systems to Enhance the Anticancer Effect of Sorafenib Drug in Hepatocellular Carcinoma and Colorectal Adenocarcinoma Cells.Nanomaterials (Basel, Switzerland) · 2021Article
- Synthetic HDL Nanoparticles Delivering Docetaxel and CpG for Chemoimmunotherapy of Colon Adenocarcinoma.International journal of molecular sciences · 2020Article
- Application and development of aptamer in cancer: from clinical diagnosis to cancer therapy.Journal of Cancer · 2020Review
- Advances in targeted nanotherapeutics: From bioconjugation to biomimicry.Nano research · 2018Article
- Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases.Pharmacological research · 2018Review
- Phytofabrication of Silver nanoparticles: Novel Drug to overcome hepatocellular ailments.Toxicology reports · 2018Article
- Enhancing regenerative approaches with nanoparticles.Journal of the Royal Society, Interface · 2017Review
- Virus-like particles: Next-generation nanoparticles for targeted therapeutic delivery.Bioengineering & translational medicine · 2017Review
- Systemically administered collagen-targeted gold nanoparticles bind to arterial injury following vascular interventions.Physiological reports · 2017Article
- Prussian blue nanoparticle-based photothermal therapy combined with checkpoint inhibition for photothermal immunotherapy of neuroblastoma.Nanomedicine : nanotechnology, biology, and medicine · 2017Article
- Potential applications of nanoparticles in cancer immunotherapy.Human vaccines & immunotherapeutics · 2017Review
- The Implications and Future Perspectives of Nanomedicine for Cancer Stem Cell Targeted Therapies.Frontiers in molecular biosciences · 2017Review
- A pyruvate decarboxylase-mediated therapeutic strategy for mimicking yeast metabolism in cancer cells.Pharmacological research · 2016Article
- Conjugating Prussian blue nanoparticles onto antigen-specific T cells as a combined nanoimmunotherapy.Nanomedicine (London, England) · 2016Article
- Activated Charge-Reversal Polymeric Nano-System: The Promising Strategy in Drug Delivery for Cancer Therapy.Polymers · 2016Review
- Toxicity studies of coumarin 6-encapsulated polystyrene nanospheres conjugated with peanut agglutinin and poly(N-vinylacetamide) as a colonoscopic imaging agent in rats.Nanomedicine : nanotechnology, biology, and medicine · 2015Article
- Aptamers and their applications in nanomedicine.Small (Weinheim an der Bergstrasse, Germany) · 2015Review
- Exploring the tumor microenvironment with nanoparticles.Cancer treatment and research · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purpose of reviewTo summarize the most recent preclinical and clinical advancements in therapeutic nano-oncology. RECENT
findingsFirst-generation nanotherapies are well tolerated in humans and evidence shows that they are efficacious, while at the same time reducing the burden of side-effects. Most of these therapies are not specifically targeted, but take advantage of enhanced passive accumulation within tumors to preferentially deliver chemotherapies that demonstrate off-target toxicities when administered as free drugs. Also, actively targeted nanotherapies are entering the clinical arena and preliminary data are encouraging. Finally, a number of exciting preclinical developments in nanotechnology provide clear evidence that nanotherapies will continue to enter the clinic and will have a significant impact in oncology. SUMMARY: A number of intriguing nanoparticle therapies are being tested in preclinical and clinical trials. Nanoparticles with increasing molecular sophistication, specific targeting properties, and unique mechanisms of action will find their way to the clinic. Certainly, nanoparticle-based therapies will be increasingly represented in drug development pipelines, and will continue to provide efficacious and well tolerated drug options for patients with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.